Access to therapy in the multicenter AIDS Cohort Study, 1989-1992

Neil M H Graham, Lisa Paula Jacobson, Victor Kuo, Joan S. Chmiel, Hal Morgenstern, Sharon L. Zucconi

Research output: Contribution to journalArticle

Abstract

The study aims were (i) to describe secular trends in the utilization of antiretrovirals, antivirals, Pneumocystis carinii pneumonia (PCP) prophylaxis, and antifungal prophylaxis and (ii) to determine whether factors such as clinical status, health services utilization, insurance status, income, education and race were associated with access to therapy. Data on utilization of therapy, health services utilization, income and insurance status were collected semiannually from October 1990 through March 1992 from 1415 homosexual/bisexual HIV-1 seropositive men in the Multicenter AIDS Cohort Study (MACS). Prevalence of therapy use according to level of immunosuppression was determined at each study visit. Clinical AIDS was defined using the 1987 CDC definition. Factors associated with use of antiretroviral therapy and PCP prophylaxis were assessed using multiple logistic regression with robust variance techniques to adjust variance estimates and significance levels for within-person correlations of drug use over time. Prevalence of zidovudine use remained relatively constant throughout the study period. In contrast, use of didanosine (21-34%), acyclovir (23-34%) and dideoxycytidine (zalcitabine) (8-25%) increased in participants with clinical AIDS. Similar trends were seen for combination antiretroviral therapy, trimethoprim-sulfamethoxazole, dapsone, ketoconazole and fluconazole. However, reported use of aerosolized pentamidine fell. After adjusting for CD4+ lymphocyte count and HIV-1 symptoms, previous HIV-related hospitalization (OR = 1.52; 95% CI = 1.22-1.91), outpatient visit (OR = 2.83; 95% CI = 2.12-3.78), having insurance (OR = 1.32; 95% CI = 1.01-1.75), college education (OR = 1.42; 95 % CI = 1.13-1.80) and white race (OR = 1.58; 95% CI = 1.21-2.07) were all associated with being on antiretroviral therapy in persons without clinical AIDS. In persons with clinical AIDS, having insurance (OR = 2.89; 95% CI = 1.04-8.02) and a previous outpatient visit (OR = 11.69; 95% CI = 1.77-77.30) were the significant variables. Factors significantly associated with being on PCP prophylaxis in multivariate models were previous hospitalization, previous outpatient visit, and college education (for subjects without clinical AIDS).

Original languageEnglish (US)
Pages (from-to)1003-1012
Number of pages10
JournalJournal of Clinical Epidemiology
Volume47
Issue number9
DOIs
StatePublished - 1994

Fingerprint

Acquired Immunodeficiency Syndrome
Cohort Studies
Pneumocystis Pneumonia
Zalcitabine
Insurance Coverage
Outpatients
Insurance
Education
Health Services
HIV-1
Hospitalization
Therapeutics
Didanosine
Pentamidine
Dapsone
Ketoconazole
Acyclovir
Zidovudine
Fluconazole
Sulfamethoxazole Drug Combination Trimethoprim

Keywords

  • AIDS
  • Didanosine
  • Dideoxycytidine
  • Health care utilization
  • HIV-1
  • Zidovudine

ASJC Scopus subject areas

  • Medicine(all)
  • Epidemiology
  • Public Health, Environmental and Occupational Health

Cite this

Graham, N. M. H., Jacobson, L. P., Kuo, V., Chmiel, J. S., Morgenstern, H., & Zucconi, S. L. (1994). Access to therapy in the multicenter AIDS Cohort Study, 1989-1992. Journal of Clinical Epidemiology, 47(9), 1003-1012. https://doi.org/10.1016/0895-4356(94)90115-5

Access to therapy in the multicenter AIDS Cohort Study, 1989-1992. / Graham, Neil M H; Jacobson, Lisa Paula; Kuo, Victor; Chmiel, Joan S.; Morgenstern, Hal; Zucconi, Sharon L.

In: Journal of Clinical Epidemiology, Vol. 47, No. 9, 1994, p. 1003-1012.

Research output: Contribution to journalArticle

Graham, NMH, Jacobson, LP, Kuo, V, Chmiel, JS, Morgenstern, H & Zucconi, SL 1994, 'Access to therapy in the multicenter AIDS Cohort Study, 1989-1992', Journal of Clinical Epidemiology, vol. 47, no. 9, pp. 1003-1012. https://doi.org/10.1016/0895-4356(94)90115-5
Graham, Neil M H ; Jacobson, Lisa Paula ; Kuo, Victor ; Chmiel, Joan S. ; Morgenstern, Hal ; Zucconi, Sharon L. / Access to therapy in the multicenter AIDS Cohort Study, 1989-1992. In: Journal of Clinical Epidemiology. 1994 ; Vol. 47, No. 9. pp. 1003-1012.
@article{9b1620f6efcf4bc3ad26f368c8c4aa72,
title = "Access to therapy in the multicenter AIDS Cohort Study, 1989-1992",
abstract = "The study aims were (i) to describe secular trends in the utilization of antiretrovirals, antivirals, Pneumocystis carinii pneumonia (PCP) prophylaxis, and antifungal prophylaxis and (ii) to determine whether factors such as clinical status, health services utilization, insurance status, income, education and race were associated with access to therapy. Data on utilization of therapy, health services utilization, income and insurance status were collected semiannually from October 1990 through March 1992 from 1415 homosexual/bisexual HIV-1 seropositive men in the Multicenter AIDS Cohort Study (MACS). Prevalence of therapy use according to level of immunosuppression was determined at each study visit. Clinical AIDS was defined using the 1987 CDC definition. Factors associated with use of antiretroviral therapy and PCP prophylaxis were assessed using multiple logistic regression with robust variance techniques to adjust variance estimates and significance levels for within-person correlations of drug use over time. Prevalence of zidovudine use remained relatively constant throughout the study period. In contrast, use of didanosine (21-34{\%}), acyclovir (23-34{\%}) and dideoxycytidine (zalcitabine) (8-25{\%}) increased in participants with clinical AIDS. Similar trends were seen for combination antiretroviral therapy, trimethoprim-sulfamethoxazole, dapsone, ketoconazole and fluconazole. However, reported use of aerosolized pentamidine fell. After adjusting for CD4+ lymphocyte count and HIV-1 symptoms, previous HIV-related hospitalization (OR = 1.52; 95{\%} CI = 1.22-1.91), outpatient visit (OR = 2.83; 95{\%} CI = 2.12-3.78), having insurance (OR = 1.32; 95{\%} CI = 1.01-1.75), college education (OR = 1.42; 95 {\%} CI = 1.13-1.80) and white race (OR = 1.58; 95{\%} CI = 1.21-2.07) were all associated with being on antiretroviral therapy in persons without clinical AIDS. In persons with clinical AIDS, having insurance (OR = 2.89; 95{\%} CI = 1.04-8.02) and a previous outpatient visit (OR = 11.69; 95{\%} CI = 1.77-77.30) were the significant variables. Factors significantly associated with being on PCP prophylaxis in multivariate models were previous hospitalization, previous outpatient visit, and college education (for subjects without clinical AIDS).",
keywords = "AIDS, Didanosine, Dideoxycytidine, Health care utilization, HIV-1, Zidovudine",
author = "Graham, {Neil M H} and Jacobson, {Lisa Paula} and Victor Kuo and Chmiel, {Joan S.} and Hal Morgenstern and Zucconi, {Sharon L.}",
year = "1994",
doi = "10.1016/0895-4356(94)90115-5",
language = "English (US)",
volume = "47",
pages = "1003--1012",
journal = "Journal of Clinical Epidemiology",
issn = "0895-4356",
publisher = "Elsevier USA",
number = "9",

}

TY - JOUR

T1 - Access to therapy in the multicenter AIDS Cohort Study, 1989-1992

AU - Graham, Neil M H

AU - Jacobson, Lisa Paula

AU - Kuo, Victor

AU - Chmiel, Joan S.

AU - Morgenstern, Hal

AU - Zucconi, Sharon L.

PY - 1994

Y1 - 1994

N2 - The study aims were (i) to describe secular trends in the utilization of antiretrovirals, antivirals, Pneumocystis carinii pneumonia (PCP) prophylaxis, and antifungal prophylaxis and (ii) to determine whether factors such as clinical status, health services utilization, insurance status, income, education and race were associated with access to therapy. Data on utilization of therapy, health services utilization, income and insurance status were collected semiannually from October 1990 through March 1992 from 1415 homosexual/bisexual HIV-1 seropositive men in the Multicenter AIDS Cohort Study (MACS). Prevalence of therapy use according to level of immunosuppression was determined at each study visit. Clinical AIDS was defined using the 1987 CDC definition. Factors associated with use of antiretroviral therapy and PCP prophylaxis were assessed using multiple logistic regression with robust variance techniques to adjust variance estimates and significance levels for within-person correlations of drug use over time. Prevalence of zidovudine use remained relatively constant throughout the study period. In contrast, use of didanosine (21-34%), acyclovir (23-34%) and dideoxycytidine (zalcitabine) (8-25%) increased in participants with clinical AIDS. Similar trends were seen for combination antiretroviral therapy, trimethoprim-sulfamethoxazole, dapsone, ketoconazole and fluconazole. However, reported use of aerosolized pentamidine fell. After adjusting for CD4+ lymphocyte count and HIV-1 symptoms, previous HIV-related hospitalization (OR = 1.52; 95% CI = 1.22-1.91), outpatient visit (OR = 2.83; 95% CI = 2.12-3.78), having insurance (OR = 1.32; 95% CI = 1.01-1.75), college education (OR = 1.42; 95 % CI = 1.13-1.80) and white race (OR = 1.58; 95% CI = 1.21-2.07) were all associated with being on antiretroviral therapy in persons without clinical AIDS. In persons with clinical AIDS, having insurance (OR = 2.89; 95% CI = 1.04-8.02) and a previous outpatient visit (OR = 11.69; 95% CI = 1.77-77.30) were the significant variables. Factors significantly associated with being on PCP prophylaxis in multivariate models were previous hospitalization, previous outpatient visit, and college education (for subjects without clinical AIDS).

AB - The study aims were (i) to describe secular trends in the utilization of antiretrovirals, antivirals, Pneumocystis carinii pneumonia (PCP) prophylaxis, and antifungal prophylaxis and (ii) to determine whether factors such as clinical status, health services utilization, insurance status, income, education and race were associated with access to therapy. Data on utilization of therapy, health services utilization, income and insurance status were collected semiannually from October 1990 through March 1992 from 1415 homosexual/bisexual HIV-1 seropositive men in the Multicenter AIDS Cohort Study (MACS). Prevalence of therapy use according to level of immunosuppression was determined at each study visit. Clinical AIDS was defined using the 1987 CDC definition. Factors associated with use of antiretroviral therapy and PCP prophylaxis were assessed using multiple logistic regression with robust variance techniques to adjust variance estimates and significance levels for within-person correlations of drug use over time. Prevalence of zidovudine use remained relatively constant throughout the study period. In contrast, use of didanosine (21-34%), acyclovir (23-34%) and dideoxycytidine (zalcitabine) (8-25%) increased in participants with clinical AIDS. Similar trends were seen for combination antiretroviral therapy, trimethoprim-sulfamethoxazole, dapsone, ketoconazole and fluconazole. However, reported use of aerosolized pentamidine fell. After adjusting for CD4+ lymphocyte count and HIV-1 symptoms, previous HIV-related hospitalization (OR = 1.52; 95% CI = 1.22-1.91), outpatient visit (OR = 2.83; 95% CI = 2.12-3.78), having insurance (OR = 1.32; 95% CI = 1.01-1.75), college education (OR = 1.42; 95 % CI = 1.13-1.80) and white race (OR = 1.58; 95% CI = 1.21-2.07) were all associated with being on antiretroviral therapy in persons without clinical AIDS. In persons with clinical AIDS, having insurance (OR = 2.89; 95% CI = 1.04-8.02) and a previous outpatient visit (OR = 11.69; 95% CI = 1.77-77.30) were the significant variables. Factors significantly associated with being on PCP prophylaxis in multivariate models were previous hospitalization, previous outpatient visit, and college education (for subjects without clinical AIDS).

KW - AIDS

KW - Didanosine

KW - Dideoxycytidine

KW - Health care utilization

KW - HIV-1

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0028088166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028088166&partnerID=8YFLogxK

U2 - 10.1016/0895-4356(94)90115-5

DO - 10.1016/0895-4356(94)90115-5

M3 - Article

VL - 47

SP - 1003

EP - 1012

JO - Journal of Clinical Epidemiology

JF - Journal of Clinical Epidemiology

SN - 0895-4356

IS - 9

ER -